Skip to main content
Premium Trial:

Request an Annual Quote

Tempus, Children's Oncology Group Expand Genomic Testing Access for Pediatric Cancer Patients

NEW YORK – Tempus announced Tuesday that it has partnered with the Children's Oncology Group to assist the latter in its Pediatric MATCH Screening Trial.

The Chicago-based bioinformatics and molecular laboratory company will provide genomic sequencing via its 648-gene xT assay to determine if a patient is a likely match for the trial. Tempus will offer this service annually for up to 300 eligible patients aged 12 months to 21 years, who have recurrent refractory solid tumors.

The trial studies how well genetic-informed treatment works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment shown to prolong survival exists.

The xT platform integrates clinical patient data with molecular data from DNA and RNA solid tumor sequencing. Specifically, it detects somatic single nucleotide variants, insertions, and deletions from DNA sequencing across 648 genes, as well as gene fusions using RNA whole-transcriptome sequencing.

The platform is also in use across several other collaborations, including a precision cancer research project with Intermountain Healthcare and a joint effort with Eli Lilly to effectively bring broad-based genomic sequencing into clinical practice.

"This collaboration will allow more pediatric patients to access genomic sequencing, which is critical for planning their treatment journey and for matching these children, adolescents, and young adults to clinical trials," Kristiyana Kaneva, senior medical director of clinical development at Tempus, said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.